Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.
Myelodysplastic syndromes - a group of serious blood cancers - are nearly five times more common in seniors than previously thought, according to a new study by researchers from the John Theurer Cancer Center at Hackensack University Medical Center.
Frank Stonebanks, Vice-President, Commercialization and Chief Commercial Officer of the Ontario Institute for Cancer Research today announced that OICR has made equity investments in three promising Ontario technologies to accelerate their commercialization.
With this notice, stockholders of EpiCept Corporation are invited to the Annual Meeting of Stockholders on June 3, 2010, at 10:00 a.m. Eastern time at the Dolce/IBM Palisades Executive Conference Center, 334 Route 9W, Palisades, New York 10964.
Celator Pharmaceuticals today announced data from animal studies demonstrating the superior bone marrow uptake of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection, its lead clinical-stage program, as well as the enhanced circulation kinetics and efficacy of its preclinical hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation were presented at the 101st Annual Meeting of the American Association for Cancer Research in Washington, DC (Abstracts 3698 and 5534).
A clinical study underway at Rex Cancer Center of Wakefield will evaluate the use of telemonitoring in managing administration of Gleevec, a drug developed and manufactured by Novartis to treat chronic myeloid leukemia.
MicroStockProfit.com announces an investment report featuring Array BioPharma Inc.. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
ARIAD Pharmaceuticals, Inc. today announced results of preclinical studies on its investigational anaplastic lymphoma kinase (ALK) inhibitor - AP26113 - showing potent inhibition of the target protein and of mutant forms that are resistant to the first-generation ALK inhibitor, which currently is in clinical trials in patients with cancer. ARIAD scientists presented these data today at the annual meeting of the American Association for Cancer Research (AACR) in Washington, D.C.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that bafetinib (formerly known as INNO-406) has received official notification from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA) that a positive opinion was made regarding the application for orphan medicinal product for the treatment of chronic myeloid leukemia (CML).
Cornerstone Pharmaceuticals, Inc., a private pharmaceutical company, with a singular focus on cancer metabolism, has announced today that U.S. regulatory clearance has been obtained for the initiation of a physician-sponsored, Phase I human clinical trial of Cornerstone's first-in-class anticancer agent, CPI-613.
EpiCept Corporation today announced that the commercial launch of Ceplene® (histamine dihydrochloride) will take place in the United Kingdom on April 20, 2010 in conjunction with the British Society for Haematology 50th Annual Scientific Meeting in Edinburgh, Scotland. Ceplene is approved in the European Union for the remission maintenance and prevention of relapse in patients with Acute Myeloid Leukemia (AML) in first remission.
The socioeconomic status of a country has long been considered a potentially significant factor in the availability of high-quality health-care interventions and even a determinant of long-term patient outcomes. A new study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation reports that in Europe, socioeconomic factors have a direct correlation to the rates and outcomes of stem cell transplantation for patients with acute myeloid leukemia (AML).
Researchers have identified a self-feeding "vicious circle" of molecules that keeps acute leukemia cells alive and growing and that drives the disease forward.
ChemGenex Pharmaceuticals announces that the U.S. Food and Drug Administration's Office of Oncology Drug Products has issued a complete response letter regarding the new drug application for OMAPRO for the treatment of adults with chronic myeloid leukemia who have failed prior therapy with imatinib and have the Bcr-Abl T315I mutation.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced plans to initiate a Phase 2 proof-of-concept clinical trial in the second half of 2010 to evaluate the effectiveness and safety of its oncology drug candidate bafetinib (formerly known as INNO-406) in patients with an advanced form of prostate cancer known as metastatic hormone-refractory prostate cancer.
Cepheid will initiate European launch of its newest addition to the GeneXpert® family of molecular diagnostic testing systems, the GeneXpert Infinity-48, at the 20th annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Vienna, Austria. The GeneXpert Infinity-48 System is the world's first and only fully-automated, random-access system designed for management of the entire molecular testing workflow — from sample data, cartridge loading and unloading, to final reporting of test results and disposal of cartridges.
Johns Hopkins Kimmel Cancer Center researchers say preliminary studies show that a vaccine made with leukemia cells may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Imatinib mesylate (Gleevec).
Work underway at St. Jude Children's Research Hospital seeks to harnesses the body's own immune cells known as natural killer, or NK, cells to help children battle cancer. NK cells are the immune system's warriors. The cells circulate widely in the body, armed with proteins, called enzymes, capable of delivering a deadly one-two punch to viruses and cancer cells.
Cyclacel Pharmaceuticals, Inc. today announced that six abstracts highlighting translational and preclinical data for Cyclacel's cell cycle inhibitor drugs have been selected for presentation at the American Association of Cancer Research (AACR) Annual Meeting, being held from April 17-21, 2010, in Washington, DC.
StockPreacher.com announces an investment report featuring Sunesis Pharmaceuticals Inc.. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
Canadian researchers have discovered a previously hidden channel to attack leukemia and other cancer cells, according to a new study published in the Journal of Biological Chemistry. The findings from the Universit- de Montr-al, Maisonneuve-Rosemont Hospital and Universit- Laval may change the way doctors treat cancer patients.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.